CAR-T Therapy: An Integrated Approach with an Experienced Partner
Summary: CAR-T cell therapies require expertise in process development to successfully scale-up manufacturing. Working with an integrated partner like Catalent gives you the ability to manufacture at clinical and commercial scale efficiently and effectively for both autologous and allogeneic cell therapies.
Quality & Regulatory Support from pre-IND to Commercialization
Summary: Catalent has made significant investments in the cell and gene therapy space with strategic acquisitions and commitment to grow and innovate.
Process Characterization & Validation with a Commercial Scale Mindset
Summary: Catalent has made significant investments in capacity expansions to meet the growing demand of our customers.
Manufacturing Strategies to Effectively Industrialize Autologous Cell Therapies
Summary: This executive summary details why maintaining a strategic view of the production-scale from early stages of development helps accelerate the time-to-market, drives process efficiencies, and reduces costs.
Manufacturing Innovation Across New Modalities
Summary: The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities…
Pharma Predictions for 2021
Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
Cell and Gene Therapy Brochure
Summary: Catalent Cell & Gene Therapy is a premier partner for innovators across the entire field of advanced biotherapeutics. Explore our development and manufacturing capabilities for allogeneic and autologous cell therapies, viral vector-based…
CPhI Festival of Pharma Roundtable: Cell & Gene Technology
Summary: In this on-demand webinar from the 2020 CPhI Festival of Pharma, panelists discuss innovative technologies and their adoption for cell and gene therapies.
Technology Integrators in Cell and Gene Therapy: Powering Innovation
Summary: Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.
Overcoming Scalability Challenges with Autologous Therapies
Summary: In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies and the various solutions available for commercial scale-up of advanced therapeutics
Overcoming Commercialization Challenges for Cell & Gene Therapies
Summary: This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.
Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness Using “Manufacturing by Design” Methodology
Summary: Allogeneic T-cell therapies are moving towards having breakthrough therapies available for market launch.
Catalent Cell & Gene Therapy, the Journey
Summary: Learn about Catalent’s journey into the Cell and Gene therapy space, overcoming challenges, and the company’s commitment to its partners.